Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Treating Hemoglobinopathies

June 21, 2019 0

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell …

News From Four Biotech Companies and Several Treatments

June 19, 2019 0

AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca (AZN) and Merck (MRK) PARP inhibitor Lynparza (olaparib) has …

Pfizer to Acquire Array Biopharma at $48 a Share

June 17, 2019 0

Pfizer to Acquire Array Pfizer (PFE) announced that it has agreed to acquire Array Biopharma (ARRY) …

bluebird bio: Why This Firm’s Stock Gained $6.37 Yesterday

June 14, 2019 0

Why has bluebird bio Been Hammered in the Market Recently? Investors should be asking why bluebird …

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

June 13, 2019 3

Nektar Announced Results for NKTR-358 During an oral session at the Annual European Congress of Rheumatology …

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression After 2 Years of Treatment

June 12, 2019 0

Good News about Novartis’ Cosentyx® for Psoriatic Arthritis Novartis (NVS) has good news for Cosentyx®. Data emerging out …

The ASCO 2019 Special Edition

June 11, 2019 0

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …

Why Vertex’s and CRISPR Therapeutics’ Stocks Are Rallying

June 7, 2019 0

Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene …

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

June 6, 2019 0

AT ASCO Gilead Sciences and Yescarta® By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology …

bluebird bio Announces a European Conditional Approval of Its Gene Therapy ZYNTEGLO™ for Transfusion-Dependent β-Thalassemia

June 4, 2019 0

Zynteglo™ from bluebird bio Gets European Conditional Approval European marketing authorization for Zynteglo follows the fastest …

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

June 4, 2019 0

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is …

Cara Therapeutics: More Positive Results from the Korsuva Product Trial for Hemodialysis Patients’ Pruritis

May 30, 2019 0

Positive Results from Korsuva for Pruritis Cara Therapeutics Postive Results from Korsuva Trial On May 29, …

Recent News from Incyte, Merck and Nektar

May 29, 2019 0

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

May 24, 2019 0

Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Treating Hemoglobinopathies

News From Four Biotech Companies and Several Treatments

Pfizer to Acquire Array Biopharma at $48 a Share

bluebird bio: Why This Firm’s Stock Gained $6.37 Yesterday

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression After 2 Years of Treatment

The ASCO 2019 Special Edition

Why Vertex’s and CRISPR Therapeutics’ Stocks Are Rallying

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

bluebird bio Announces a European Conditional Approval of Its Gene Therapy ZYNTEGLO™ for Transfusion-Dependent β-Thalassemia

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

Cara Therapeutics: More Positive Results from the Korsuva Product Trial for Hemodialysis Patients’ Pruritis

Recent News from Incyte, Merck and Nektar

Genomes, Genes and Gene Therapies

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

Vertex: Good News and Good Decisions

Array BioPharma: Great News and a Learning Experience

The Medicines Company: Are Inclisiran’s Clinical Trial Results Impressive?

Another Late-Stage Firm with Impressive Technology and Promising Products

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative Market Day